

Left atrial appendage occlusion for atrial fibrillation and bleeding diathesis

Balrik Singh Kailey¹, Michael Koa-Wing¹, Nilesh Sutaria¹, Tom Mott², Sohaib SMA¹, Norman Qureshi¹, Christine Shi¹, Pritpal Padam¹, James Howard¹, and Prapa Kanagaratnam¹

¹Imperial College London

²Abbott Cardiovascular UK Ltd



June 7, 2023



Abstract

Background: Patients with AF and likelihood of bleeding can undergo left atrial appendage occlusion (LAAO) as an alternative method of stroke prophylaxis. Short-term anti-thrombotic drugs are used post-procedure to offset the risk of device-related thrombus, evidence for this practice is limited. **Objectives:** To investigate optimal post-implant antithrombotic strategy in high bleeding-risk patients. **Methods:** Patients with AF and high-risk for both stroke and bleeding undergoing LAAO were advised their peri-operative drug therapy by a multi-disciplinary physician panel. Those deemed to be at higher risk of bleeding from anti-thrombotic drugs were assigned to minimal treatment with no antithrombotics or aspirin-alone. The remaining patients received standard care (STG) with a 12week course of dual-antiplatelets or anticoagulation post-implant. We compared mortality, device-related thrombus, ischemic stroke and bleeding events during the 90 days post-implant and long-term. Event-free survival was assessed using Kaplan-Meier survival analysis, with logrank testing for statistical significance. **Results:** 75 pts underwent LAAO of whom 63pts(84%) had a prior serious bleeding event. The 42pts on minimal treatment were older(74.3 ± 7.7 vs 71.2 ± 7.2) with higher HASBLED score (3.6 ± 0.9 vs 3.3 ± 1.2) than the 33pts having standard care. There were no device-related thrombi or strokes in either group at 90 days post-procedure; STG had more bleeding events (5/33vs0/42, $p=0.01$) with associated deaths (3/33vs0/42, $p=0.05$). During long-term follow up (median 2.2yrs), all patients transitioned onto no antithrombotic drugs (43pts(61%)) or a single-antiplatelet (29pts(39%)). There was no evidence of early minimal treatment adversely affecting long-term outcomes. **Conclusions:** Short-term anti-thrombotic drugs may not be needed after LAAO implant in patients with high bleeding risk and could be harmful. Larger, prospective studies would be warranted to test these findings.


Hosted file

Final LAAO manuscript.docx available at <https://authorea.com/users/626465/articles/647874-left-atrial-appendage-occlusion-for-atrial-fibrillation-and-bleeding-diathesis>





Strata	0	25	50	75	100
Conventional	33	29	28	28	0
Minimal	42	42	42	42	0



Strata	0	1000	2000	3000	4000
Conventional	33	17	7	6	0
Minimal	42	16	5	2	0

